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The potential implication of eosinophil activation in the pathogenesis  
of childhood asthma 
INTRODUCTION 
Asthma is recognized as an eosinophil mediated 
inflammation of the airways1. Eosinophils are major 
contributors to the damage in the airways of 
asthmatic patients which when  activated, 
degranulate and release granules that contain 
cytotoxic cationic proteins including the major 
basic protein, eosinophil peroxidase, eosinophil 
cationic protein, eosinophil protein "X" (EPX), and 
membrane lipid mediators. These products have 
deleterious effects on the airway tissues and result 
in destruction of mucosal and smooth muscle layers 
which lead to the inability to clear bronchial 
secretions and the production of constrictor factors 
that cause bronchoconstriction, increased vascular 
permeability and development of airway 
hyperresponsiveness. Also, these products influence 
the accumulation and maintenance of eosinophilic 
responses at the site of inflammation2. So, 
measuring these proteins in blood to monitor 
inflammation in bronchial asthma patients is of a 
special importance in pediatric practice because 
lung function tests are less easily performed in 
young children3. Several studies have been done to 
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Background: Asthma is now recognized as an eosinophil mediated 
inflammation of the airways. Pulmonary function tests are less easily 
performed in young children. So, measuring markers of eosinophil 
activation is of special importance in pediatric practice. 
Objective: This study aimed at evaluating the role of eosinophil protein X 
(EPX) as a marker for assessment of asthma attack severity and control of 
the exacerbation. 
Methods: Serum EPX was measured in 35 asthmatic Egyptian children aged 
between 7 and 10 and 35 age and sex matched healthy children using 
radioimmunoassay technique (RIA). Asthmatic patients were graded 
according to severity of the attack into mild, moderate and severe and the 
measurement was performed during and after the resolution of acute asthma 
attack. In addition, complete hemogram, total serum IgE, arterial blood 
gases and stool analysis were performed and peak expiratory flow rate 
(PEFR) was assessed in asthmatic children during and after acute 
exacerbation. 
Results: Serum concentrations of EPX, total serum IgE and absolute 
eosinophilic count (AEC) were significantly higher in asthmatic children 
than healthy controls (P<0.001). Serum EPX and AEC were significantly 
higher in all studied groups before treatment compared to the corresponding 
levels of the same patients after treatment (P<0.001). Total serum IgE was 
significantly higher only in mild and moderate asthma before treatment 
(P<0.001). Serum EPX level was significantly elevated among patients with 
severe attacks (84.70 ± 7.18 μg/L) than those with moderate attacks (67.2 ± 
5.31 μg/L) and patients with mild attacks (53.47 ± 11.47 μg/L)(P<0.001). It 
was negatively correlated to PEFR measurement during attacks (r=-0.75, 
P<0.05). A significant reduction in serum EPX and AEC was observed after 
the resolution and improvement of pulmonary function. Meanwhile, total 
serum IgE decreased after treatment with the resolution of asthma attack, 
yet it remained significantly higher than that of controls (P<0.001). 
Conclusion: Our findings support the concept that EPX may be implicated 
in the pathogenesis of asthma and highlights its importance in monitoring 
the severity and control of asthma exacerbation. Hence, it might represent 
an objective guide of treatment efficacy. 
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measure the eosinophil granule proteins in children 
with bronchial asthma and the results of these 
studies suggest that serum markers of eosinophil 
activation correlate with airway function in 
childhood asthma and may be of value in assessing 
the severity of the disease4. 
The aim of this study was to evaluate the role of 
eosinophil protein X as a marker for assessment of 




This follow up case-control study was carried out 
on 35 Egyptian asthmatic children (20 boys and 15 
girls) aged between 7 and 10 years with a mean of 
8.3±1.2 years. These patients were recruited from 
the Outpatient Pediatric Chest Clinic, Children's 
Hospital, Ain Shams University during the period 
from January to December 2002. Patients were 
assessed for asthma severity according to GINA 
guidelines5 and were categorized as mild (n=10), 
moderate (n= 15) and severe asthmatics (n= 10). 
The patients were evaluated during acute asthmatic 
attacks and were followed up until the attack 
subsided clinically and then re-evaluated after 2 
weeks of treatment (bronchodilators and short term 
inhaled steroids). Among these patients, 80% had 
family history of allergy and parental smoking. 
Exclusion criteria for the patients were: the 
presence of acute lower respiratory tract infection, 
fever, parasitic infestation (by stool analysis) and 
treatment with long-term corticosteroids whether 
inhaled or systemic. 
Control group: thirty-five age and sex matched 
healthy children were included in this study to serve 
as controls. They had no personal or family history 
of allergic diseases. 
 
Methods: 
All the studied children were subjected to the 
following: 
• Clinical evaluation as regards family history of 
atopy, the duration and severity of symptoms, 
records of drug therapy as well as assessment of 
asthma severity. PEFR was measured by a Mini-
Wright peak flow meter (Clement Clarke 
International Ltd, Edinburgh, Essex CM202 DE, 
England). 
• Laboratory investigations included complete 
hemogram including total and differential 
leukocytic counts (Coulter counter T660, 
Coultronics, France), blood gas analysis (blood gas 
analyzer Mod. 995, Hb-Trust Medical Company), 
stool analysis, total serum IgE level using ELISA 
technique (Medix Biotech Inc., Agenzyme 
Company, San Carios CA, USA). 
Serum eosinophil protein X (EPX) was measured 
by radioimmunoassay technique (RIA)(4) using a 
commercially available kits supplied by Pharmacia 
Company, (100 Route 206 North Peapack, New 
Jersey 07977, USA). 
Serum "EPX", total serum IgE, absolute 
eosinophilic count (AEC) and PEFR were measured 
twice for each asthmatic patient (during and after 
resolution of acute asthma attack (with a 2 weeks 
interval).    
Sample collection: 
Blood specimens were obtained under complete 
aseptic condition from the studied individuals by: 
Arterial puncture (radial artery): 1 ml blood in 
heparinized syringe for pH and blood gas analysis 
(Kept in ice till analyzed). 
Venipuncture: 1 ml was collected in a test tube 
containing EDTA for complete hemogram and 3ml 
in a plain dried tube left to clot at room temperature 
then centrifuged at 3000 rpm to separate serum for 




Data processing of the results statistical analysis 
statistically using SSPS soft ware package (Version 
“8”, 1997 USA). Student’s t test was used to 
compare the mean values of parametric data and 
ANOVA for evaluating quality of several groups. 
 
RESULTS 
The mean serum EPX concentration, total serum 
IgE and absolute eosinophilic count (AEC) were 
significantly higher while PEFR was significantly 
lower in asthmatic children than in healthy controls 
(P<0.001) (table 1). 
The serum EPX levels and AEC were significantly 
dropped whereas PEFR significantly increased with 
the resolution of the attacks (P<0.001). Total serum 
IgE was significantly higher only in mild and 
moderate asthma during the attack compared to the 
level in remission (P<0.001) (table 2). 
The relationship of asthma severity to different 
laboratory parameters was studied by ANOVA test. 
This revealed a significant direct relationship with 
EPX, serum total IgE and AEC, whereas the 
relation with PEFR was a significant inverse one 
(fig.1). 
Serum EPX correlated negatively with PEFR (r=-
0.75, P<0.05) and positively correlated with AEC 
and the mean serum IgE level (r=0.56, r=0.59 
respectively, P<0.05). 
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No significant correlation could be found between 
serum EPX and the duration of illness. Serum EPX 
did not differ significantly between patient with 
history of other atopic diseases (27±65µg/L) and 
those with no history of atopic diseases 
(26±27µg/L). Following treatment and resolution of 
acute asthma symptoms with therapy the mean 
serum EPX, AEC and PEFR became insignificantly 
differed from the control values (P>0.05). The 
mean total serum IgE level decreased after 
treatment, yet it remained significantly higher than 








Table 1: Comparison between asthmatic patients during attacks and controls as regard serum EPX, total serum 
IgE, AEC and PEFR. 





 mean±SD mean±SD  
Serum EPX (µg/L) 23.95±4.38 79.71±6.90 P<0.001 
Total serum IgE (IU/ml) 34.73±7.38 270.30±160.40 P<0.001 
AEC(%) 1.82±0.85 12.30±1.40 P<0.001 
PEFR (%) 97.36±9.36 73.20±2.24 P<0.001 
 P<0.001= highly significant 
 
Table 2: Serum EPX, total IgE, AEC and PEFR in the study groups during acute attacks and in remission. 
  
Mild asthmatics 











































P <0.001 <0.001 <0.001 












































P <0.001 <0.001 <0.001 
P>0.05= non significant      P<0.05=significant        P<0.001=highly significant    
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Figure 1: Relation of the laboratory findings and PEFR to the severity of asthma (P 
values reflect the differences among the groups by ANOVA test). 
 
Table 3:  Comparison between patients groups and controls as regards  
































P >0.05 >0.05 >0.05 
































P >0.05 >0.05 >0.05 
P>0.05 = non significant ,  P<0.001= highly significant 
 
DISCUSSION 
Eosinophils are involved in the inflammatory 
response in asthma and their basic proteins play a 
major pathophysiological role in this process as 
they cause cytoxic damage to the airways 
epithelium in asthma. The serum levels of these 
basic proteins have been used to monitor the 
ongoing asthmatic disease. Assessment of 
eosinophil derived proteins in various body fluids 
(serum, urine and nasal lavage) could be used for 
monitoring disease activity of childhood asthma7. 
So, this study aimed at evaluating serum EPX as a 
marker for assessment of disease severity and 
prognosis in asthmatic children. 
The results of this study revealed that 80% of 
patients had positive family history of allergy and 
parental smoking. This finding was in agreement 
with that of Cohen8 who stated that 75% of 
asthmatic patients had a positive family of asthma 
or other atopic disorders. As regards parental 
smoking, Wright et al9 found that parental smoking 
was associated with an increased risk of asthma in 
children. 
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In fact, the role of serum EPX was evident in our 
results since its concentrations was significantly 
increased in asthmatic children as compared with 
the control group. In this regard, Remes et al10 and 
Koller et al7 found that the level of serum EPX was 
significantly raised in children with bronchial 
asthma compared with healthy control subjects. 
Also, Boner et al11 and Oymar12 reported that levels 
of EPX were higher in children with asthma during 
acute attacks than in controls. 
An important aim of this study was to evaluate 
serum EPX in asthmatic children during and after 
the resolution of an asthma attack. Serum EPX 
significantly increased in all asthmatic children 
during exacerbations compared to the values 
observed with the resolution of the attacks 
(P<0.001). In support of our results, Labbe et al (1) 
reported that there was significant reduction in the 
level of EPX in asthmatic children after treatment 
when compared to their corresponding value before 
treatment. 
Another goal of this study was to evaluate whether 
the level of serum EPX was influenced by the 
severity of asthma attack. The results showed that 
during exacerbations of asthma the more severe the 
grade of asthma was, the higher was the mean 
serum EPX. Moreover, serum EPX correlated 
negatively to PEFR in asthmatic children. These 
findings denote that EPX production is positively 
correlated with the degree of bronchospasm. In 
agreement with our results Breuer et al(13) 
documented that the levels of EPX in serum and 
body fluids were correlated with disease activity 
and severity in atopic respiratory disease. Also, 
Lugosi et al14 and Shirakawa et al15 concluded that 
levels of EPX in serum and urine were negatively 
correlated with parameters of pulmonary function 
in asthmatic children. Recently, Bahceciler et al16 
stated that while EPX concentrations had increased, 
pulmonary function tests had decreased 
significantly in asthmatic children during acute 
attacks. 
It is of value also to document that with resolution 
of the attacks, the levels of EPX became 
insignificantly different from controls. This could 
be a reflection of decreased recruited eosinophilis to 
the site of allergic inflammation. Therefore, it could 
be a useful marker in the follow up of disease 
severity and activity. In agreement with our results 
Vila et al17 reported that eosinophil products 
including EPX have been related to bronchial 
inflammatory reactions and their levels have been 
shown to decline after treatment and the resolution 
of an asthma attack. Also, Storm et al18 stated that 
measurement of serum EPX is helpful in 
monitoring therapy in asthmatic children. 
Moreover, Labbe et al1 found that EPX levels were 
higher in children with asthma than in controls and 
after treatment there were significant reduction in 
the level of EPX in these asthmatic children, so, 
they concluded that EPX levels were sensitive and 
useful to the clinician in the evaluation of 
manifestations of airway inflammation in asthmatic 
children. 
On studying serum IgE level in all asthmatics 
during and after resolution of an asthma attack, it 
was found that it increased with increased severity 
of the disease and in comparison to controls. 
Similarly, Boner et al.11 found that there was 
significant increase in the level of serum IgE in 
asthmatic children during acute attacks. Also, 
Khadadah et al19 recorded that total serum IgE was 
elevated above 200 IU/L in 63% of asthmatic 
compared to controls. 
The results of this study showed that the AEC was 
increased with increasing asthma severity and also 
it was higher during the attack compared to the 
count after the resolution and to controls. Lastly, no 
significant difference between the three studied 
groups after treatment and controls as regards the 
mean value of AEC. In agreement with our results 
Alvarez et al20 and Oymer et al12 found that the 
AEC was higher in asthmatics than in controls. Jang 
et al2 found that moderate and severe asthmatics 
had significantly higher eosinophilic counts 
compared with mild asthmatics. Finally, Metso et 
al21 stated that the AEC was decreased in asthmatics 
after treatment compared with controls. In the 
current study, PEFR decreased significantly in 
patients as compared to healthy controls and in all 
studied groups during the attack compared to the 
corresponding values after the resolution. Also, it 
decreased significantly with increased asthma 
severity and it increased with improvement of the 
clinical condition after treatment Bahceciler et al16 
found that PEFR decreased in asthmatics during 
acute attacks and improved (increased) with 
improvement of their condition. 
In conclusion, serum EPX increases with increased 
acute asthma severity and correlates negatively with 
PEFR. Its levels are higher during asthma 
exacerbations and declines towards normality with 
the resolution of the attacks. Therefore, EPX may 
be implicated in the pathogenesis of asthma and 
reflect the degree of severity of asthma. This 
highlights the importance of EPX as an 
inflammatory marker detecting both the evolution 
and the control of asthma exacerbation. Hence, it 
might represent an objective guide of treatment 
efficacy. 
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